This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination.
No takes yet. Share an insight, caveat, or question.
König et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: